TY - JOUR
T1 - Scope of lipid nanoparticles in neuroscience
T2 - Impact on the treatment of neurodegenerative diseases
AU - Segura-Uribe Julia, J.
AU - Jimena, Ciprés Flores Fabiola
AU - Dalet, Farfán García Eunice
AU - Guadalupe, Trujillo Ferrara José
AU - Antonio, Soriano Ursúa Marvin
N1 - Publisher Copyright:
© 2017 Bentham Science Publishers.
PY - 2017
Y1 - 2017
N2 - Background: Lipid nanoparticles have been studied mainly as a means of transporting and releasing drugs. A special emphasis has been placed on designing nanoparticles that improve the delivery of drugs with targets in the central nervous system. Methods: The biomedical literature was searched for basic and clinical studies. The recent applications are described and related with their bioactivities. Results: The current review compiles data on the components and features of lipid nanoparticle systems as well as the necessary conditions for their selective action. As an example of their application, we present data from preclinical and clinical studies on lipid nanoparticles used as potent and efficient agents in the diagnosis and treatment of some neurodegenerative maladies, including Parkinson’s disease. Conclusion: Current evidence supports the application of lipid nanoparticles for designing drugs carriers for neurodegenerative diseases. Also, we have gathered data that suggests a role of drug-free lipid nanoparticles as neuroprotective or preventive agents during neurodegenerative processes.
AB - Background: Lipid nanoparticles have been studied mainly as a means of transporting and releasing drugs. A special emphasis has been placed on designing nanoparticles that improve the delivery of drugs with targets in the central nervous system. Methods: The biomedical literature was searched for basic and clinical studies. The recent applications are described and related with their bioactivities. Results: The current review compiles data on the components and features of lipid nanoparticle systems as well as the necessary conditions for their selective action. As an example of their application, we present data from preclinical and clinical studies on lipid nanoparticles used as potent and efficient agents in the diagnosis and treatment of some neurodegenerative maladies, including Parkinson’s disease. Conclusion: Current evidence supports the application of lipid nanoparticles for designing drugs carriers for neurodegenerative diseases. Also, we have gathered data that suggests a role of drug-free lipid nanoparticles as neuroprotective or preventive agents during neurodegenerative processes.
KW - Central nervous system
KW - Drug delivery
KW - Nanoliposomes
KW - Nanoparticles
KW - Neurodegenerative disease
KW - Parkinson’s disease
UR - http://www.scopus.com/inward/record.url?scp=85032874403&partnerID=8YFLogxK
U2 - 10.2174/1381612823666170301123504
DO - 10.2174/1381612823666170301123504
M3 - Artículo de revisión
C2 - 28260513
SN - 1381-6128
VL - 23
SP - 3120
EP - 3133
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 21
ER -